Also, despite not meeting the diagnostic morphologic criteria of MDS (low dysplastic burden in the bone marrow), the presence of the TP53 mutation with VAF of > 50%, KMT2A mutation, and the independent minor neoplastic clone with myeloid features raised the suspicion of an evolving concurrent high-risk MDS. This evidence concerns the gene TP53 and myelodysplastic syndrome.